Source / episode info
- **Episode:**71
- **Title:**Divine Intervention Episode 71 – Oncology Pharm Part 2 (Final Part/Cell Biology Episode)
- **Published:**2019-01-10
- Source:Episode page
One-liner
This episode covers the mechanisms of action and clinical uses of major anti-cancer drug classes, including alkylating agents (e.g., cyclophosphamide), topoisomerase inhibitors, microtubule inhibitors (vinca alkaloids vs. taxanes), tyrosine kinase inhibitors (TKIs), hormone receptor modulators (SERMs/Aromatase Inhibitors), and proteasome inhibitors (Bortezomib).
High-yield summary
- Alkylating Agents: These drugs crosslink DNA by chemically modifying bases, often at the N7 position of guanine. Cyclophosphamide metabolites form acrolein, a vesicant causing hemorrhagic cystitis; prevention requires Mesna or aggressive diuresis.
- Microtubule Inhibitors: The two classes are defined by their action: Vinca alkaloids (e.g., vincristine) prevent polymerization, leading to neurotoxicity; Taxanes (e.g., paclitaxel) prevent depolymerization. Always prioritize vincristine for peripheral neuropathy on board exams.
- Targeted Therapy: Drugs ending in "-nib" are generally Tyrosine Kinase Inhibitors (TKIs). These agents target specific overactive receptors, such as the BCR-ABL fusion protein (Imatinib) or EGFR/HER1.
- Hormone Modulation: Aromatase inhibitors (Anastrozole, Letrozole) block estrogen synthesis from androgens, primarily used in postmenopausal women; SERMs like Tamoxifen are selective modulators with differential effects on breast, uterus, and bone tissue.
- Proteasome Inhibition: Bortezomib inhibits the 20S proteasome subunit, preventing the breakdown of NF-B inhibitors (like IB), thereby halting cancer cell proliferation in multiple myeloma.
Learning objectives
- Differentiate between the mechanisms of action of various anti-cancer drug classes (e.g., alkylating vs. topoisomerase inhibitors).
- Correlate specific side effects (e.g., hemorrhagic cystitis, peripheral neuropathy) with their causative drugs and metabolites.
- Understand the role of hormone receptor modulators (SERMs, Aromatase Inhibitors) in different menopausal states and tissues.
- Identify the clinical indications for targeted therapies based on genetic mutations or overexpressed receptors (e.g., HER2, BCR-ABL).
- Recognize the principles of drug synergy and antagonism, such as combining Procarbazine with SSRIs/MAOIs to avoid serotonin syndrome.
Board exam buzzwords